• Azenta launched a restructuring in its Multiomics segment to consolidate its North American lab network, streamline operations, cut jobs, close three sites.
• Estimated pre-tax charges of $11 million to $13 million, including about $9 million of asset impairments tied to exited leased facilities.
• Future cash costs seen at about $7 million, mainly severance and restructuring expenses of roughly $3 million.
• Most charges expected in fiscal 2027; actions targeted to be largely completed by March 31, 2027.
• Annualized cost savings projected at about $11 million once fully implemented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azenta Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-065292), on October 07, 2026, and is solely responsible for the information contained therein.